Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely nortriptyline (as nortriptyline hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cilazapril (som cilazaprilmonohydrat) 500 mikrogram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cilazapril (som cilazaprilmonohydrat) 500 mikrogram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin (som amoxicillintrihydrat) 875 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin (som amoxicillintrihydrat) 875 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin (som amoxicillintrihydrat) 875 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
tiagabin (som tiagabinhydrokloridmonohydrat) 5 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
tiagabin (som tiagabinhydrokloridmonohydrat) 5 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely imatinib (as imatinib mesilate) 400 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely imatinib (as imatinib mesilate) 400 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Levothyroxine sodium anhydrous 75 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 75 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely conjugated estrogen 625 microgram and medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely conjugated estrogen 625 microgram and medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely conjugated estrogen 625 microgram and medroxyprogesterone acetate 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 100 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 100 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lofepramine (as lofepramine hydrochloride) 70 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lofepramine (as lofepramine hydrochloride) 70 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 10 milligram och levodopa 100 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 10 milligram och levodopa 100 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa (som karbidopamonohydrat) 10 milligram och levodopa 100 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Quinagolide (as quinagolide hydrochloride) 75 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Quinagolide (as quinagolide hydrochloride) 75 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
levofloxacin (som levofloxacinhemihydrat) 250 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
levofloxacin (som levofloxacinhemihydrat) 250 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
ibandronatsyra (som ibandronatnatriummonohydrat) 50 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
ibandronatsyra (som ibandronatnatriummonohydrat) 50 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Salbutamol (as salbutamol sulfate) 4 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Salbutamol (as salbutamol sulfate) 4 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 12,5 milligram och levodopa 50 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 12,5 milligram och levodopa 50 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa (som karbidopamonohydrat) 12,5 milligram och levodopa 50 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely imatinib (as imatinib mesilate) 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely imatinib (as imatinib mesilate) 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Pergolide (as pergolide mesilate) 250 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Pergolide (as pergolide mesilate) 250 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely paroxetine (as paroxetine hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely paroxetine (as paroxetine hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cisaprid (som cisapridmonohydrat) 10 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cisaprid (som cisapridmonohydrat) 10 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely fluphenazine hydrochloride 500 microgram and nortriptyline (as nortriptyline hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely fluphenazine hydrochloride 500 microgram and nortriptyline (as nortriptyline hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely fluphenazine hydrochloride 500 microgram and nortriptyline (as nortriptyline hydrochloride) 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely quetiapine (as quetiapine fumarate) 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely quetiapine (as quetiapine fumarate) 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Reboxetine (as reboxetine mesilate) 4 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Reboxetine (as reboxetine mesilate) 4 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely pergolide (as pergolide mesilate) 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely pergolide (as pergolide mesilate) 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely levothyroxine sodium anhydrous 25 microgram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely pergolide (as pergolide mesilate) 50 microgram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely pergolide (as pergolide mesilate) 50 microgram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clopidogrel (as clopidogrel bisulfate) 75 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clopidogrel (as clopidogrel bisulfate) 75 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely fluphenazine hydrochloride 1.5 milligram and nortriptyline (as nortriptyline hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely fluphenazine hydrochloride 1.5 milligram and nortriptyline (as nortriptyline hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely fluphenazine hydrochloride 1.5 milligram and nortriptyline (as nortriptyline hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 250 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 250 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 250 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Ruxolitinib (as ruxolitinib phosphate) 10 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Ruxolitinib (as ruxolitinib phosphate) 10 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely darunavir (as darunavir ethanolate) 400 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely darunavir (as darunavir ethanolate) 400 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 38 microgram and liothyronine sodium 9 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Levothyroxine sodium anhydrous 38 microgram and liothyronine sodium 9 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 38 microgram and liothyronine sodium 9 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
cilazapril (som cilazaprilmonohydrat) 2,5 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cilazapril (som cilazaprilmonohydrat) 2,5 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely lapatinib (as lapatinib ditosylate) 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely lapatinib (as lapatinib ditosylate) 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Darunavir (as darunavir ethanolate) 600 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Darunavir (as darunavir ethanolate) 600 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
atorvastatin (som atorvastatinkalciumtrihydrat) 10 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
atorvastatin (som atorvastatinkalciumtrihydrat) 10 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely darunavir (as darunavir ethanolate) 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely darunavir (as darunavir ethanolate) 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin (som amoxicillintrihydrat) 250 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin (som amoxicillintrihydrat) 250 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin (som amoxicillintrihydrat) 250 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
tiagabin (som tiagabinhydrokloridmonohydrat) 10 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
tiagabin (som tiagabinhydrokloridmonohydrat) 10 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Fenoprofen (as fenoprofen calcium) 300 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Fenoprofen (as fenoprofen calcium) 300 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Levothyroxine sodium anhydrous 50 microgram oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Levothyroxine sodium anhydrous 50 microgram oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin (som amoxicillintrihydrat) 500 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin (som amoxicillintrihydrat) 500 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin (som amoxicillintrihydrat) 500 milligram och klavulansyra (som kaliumklavulanat) 125 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
cilazapril (som cilazaprilmonohydrat) 5 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cilazapril (som cilazaprilmonohydrat) 5 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
tiagabin (som tiagabinhydrokloridmonohydrat) 15 milligram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
tiagabin (som tiagabinhydrokloridmonohydrat) 15 milligram, oral tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Aliskiren (as aliskiren fumarate) 150 mg and amlodipine (as amlodipine besilate) 5 mg and hydrochlorothiazide 12.5 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|